; line-height: 19.2pt;">近年来,乳腺癌成为世界上第二大常见的癌症,且具有很高的死亡率。截至2012年为止近170万女性已被诊断为乳腺癌。本研究选取了120例乳腺癌患者,在低分离佐剂放射治疗前,接受改良乳房根治切除术(RMR)并使用蒽环抗生素以及紫杉烷进行化疗,发现晚期和皮下组织毒性与癌症放射疗法具有相关性。研究使用单变量对数回归分析并预测年龄(>50岁)与使用紫杉烷化疗晚期肤与皮下组织毒性的相关性。结果显示,大于50岁的患者具有皮肤毒性的比例较高,但其风险性并不明显。因此,在低分离佐剂放射疗程中,年龄和紫杉烷化疗并不影响乳腺切除术后患者晚期皮肤与皮下组织毒性的治疗。而晚期皮肤及皮下组织毒性的严重程度受治疗因素和患者自身因素的影响。治疗因素包括分离的程度,分次剂量,总剂量,组织照射体积,照射类型以及化疗;患者自身因素包括乳房大小,是否吸烟,年龄以及伤口感染。此外,患者的体质也是影响正常组织毒性的风险因素之一。

 

Associations of Age and Chemotherapy with Late Skin and Subcutaneous Tissue Toxicity in a Hypofractionated Adjuvant Radiation Therapy Schedule in Post-mastectomy Breast Cancer Patients

Mohammad Akram1, Ghufran Nahid1, Shahid AliSiddiqui1, Ruquiya Afrose2

1Department of Radiotherapy, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India;

2Department of Pathology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India

 

Aim: This retrospective study was conducted to evaluate the associations of age and two different types of

chemotherapy regimens with late skin and subcutaneous tissue toxicities in an adjuvant hypofractionated

radiation therapy (HFRT) schedule.

Methods: We retrospectively reviewed the records of 120 breast cancer patients. Patients underwent modified

radical mastectomy (MRM) and received anthracycline? and taxane?based chemotherapy before the application of HFRT. Late skin and subcutaneous toxicity were evaluated in accordance with the Radiation Therapy Oncology Group grading scheme. Univariate logistic regression analysis was used to predict the associations of old age (> 50) and taxane?based chemotherapy with late skin and subcutaneous tissue toxicities.

Results: Grade 2 skin toxicity was found in 44 (42.3%) patients and Grade 2 subcutaneous tissue toxicity

was found in 38 (36%) patients. Neither Grade 3 nor Grade 4 toxicity was observed. There was higher but not statistically significant risk of Grade 2 skin and subcutaneous tissue toxicity in patients over 50 years old.

Types of chemotherapy were not significantly associated with Grade 2 skin toxicity and subcutaneous tissue toxicity.

Conclusion:Old age (> 50) and taxane?based chemotherapy do not adversely affect late skin and subcutaneous

tissue toxicity in adjuvant HFRT schedule in post?MRM breast cancer patients.

Key words: Age, breast cancer, chemotherapy, hypofractionation, skin and subcutaneous tissue toxicity

 

From:Cancer Translational Medicine 2015;1(2):35–38